Literature DB >> 10374872

Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes.

M Kitagawa1, M Takahashi, S Yamaguchi, M Inoue, S Ogawa, K Hirokawa, R Kamiyama.   

Abstract

Nitric oxide (NO) is a biological mediator which is synthesized from L-arginine by a family of nitric oxide synthases (NOS). We have studied the expression of the inducible NOS (iNOS) by bone marrow cells from the patients with myelodysplastic syndromes (MDS) at the mRNA level by RT-PCR assay and at the protein level by immunohistochemical staining using a specific anti-iNOS monoclonal antibody. The iNOS message was present in 92% of bone marrow tissues from MDS patients (11 out of 12) by an examination using RT-PCR. Basically, iNOS message was negative or very weak in control (1/9) and AML (0/7) cases. This was supported by immunohistochemical findings that the iNOS was positive in most of the bone marrow samples from MDS patients (9 out of 12), while bone marrow cells of control (O out of 12) and AML (O out of 5) cases were basically negative. Double immunostaining for CD68 antigen, which is a marker for macrophage lineage cells, and iNOS was performed on MDS bone marrow sections. iNOS was dominantly localized to bone marrow macrophages, although a part of myeloid cells were also positively stained with anti-iNOS antibody in a part of cases. These results indicated that there is some in vivo induction of iNOS expression for local NO production that might be involved in the dysregulation of hematopoiesis in bone marrow of MDS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10374872     DOI: 10.1038/sj.leu.2401407

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 2.  Immunologic aspects of hypoplastic myelodysplastic syndrome.

Authors:  Rodrigo T Calado
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 3.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

4.  Friend leukemia virus infection enhances DNA damage-induced apoptosis of hematopoietic cells, causing lethal anemia in C3H hosts.

Authors:  Masanobu Kitagawa; Shuichi Yamaguchi; Maki Hasegawa; Kaoru Tanaka; Toshihiko Sado; Katsuiku Hirokawa; Shiro Aizawa
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome.

Authors:  Jana Štikarová; Jiří Suttnar; Kristýna Pimková; Leona Chrastinová-Mášová; Jaroslav Čermák; Jan E Dyr
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388

Review 6.  Bone marrow niches in myeloid neoplasms.

Authors:  Masanobu Kitagawa; Morito Kurata; Iichiroh Onishi; Kouhei Yamamoto
Journal:  Pathol Int       Date:  2019-11-10       Impact factor: 2.534

Review 7.  Immune Mechanisms in Myelodysplastic Syndrome.

Authors:  Andreas Glenthøj; Andreas Due Ørskov; Jakob Werner Hansen; Sine Reker Hadrup; Casey O'Connell; Kirsten Grønbæk
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.